Top Suppliers:I want be here
Related CAS#:
3690-10-6 155831-90-6
34340-05-1 69776-97-2
63500-40-3 1158522-08-7
940364-43-2 134104-43-1
131615-57-1 6906-52-1
1856093-94-1 930439-75-1
1018584-77-4 1375289-11-4
849349-65-1

3690-10-6

3690-10-6 structure
3690-10-6 structure
Name zebularine
Synonyms 4-Deoxyuridine
1--D-Ribofuranosyl-2(1H)-pyrimidinone
4-Deoyuridine
2(1H)-PyriMidinone,1-b-D-ribofuranosyl
1-(β-D-Ribofuranosyl)pyrimidin-2(1H)-one
2(1H)-Pyrimidinone, 1-β-D-ribofuranosyl-
Pyrimidin-2-one b-Ribofuranoside
Zebularine
[14C]-Zebularine
1-b-D-Ribofuranosyl-2(1H)-pyrimidinone
2(1H)-Pyrimidinone, 1-.β.-D-ribofuranosyl-
Pyrimidin-2-one-D-Ribofuranoside
1-(β-D-Ribofuranosyl)-2(1H)-pyrimidinone
Description Zebularine (NSC309132; 4-Deoxyuridine) is a DNA methyltransferase inhibitor; also an inhibitor of cytidine deaminase with a Ki of 0.95 μM.
Related Catalog
Target

DNMT1

DNMT3a/3L

Cytidine deaminase:0.95 μM (Ki)

Autophagy

In Vitro Zebularine exerts its demethylation activity by stabilizing the binding of DNMTs to DNA, hindering the methylation and decreasing the dissociation, thereby trapping the enzyme and preventing turnover even at other sites. zebularine enhances tumor cell chemo- and radiosensitivity and has antimitogenic and angiostatic activities[1]. Zebularine inhibits DNA methylation and reactivates a gene previously silenced by methylation. Zebularine induces the myogenic phenotype in 10T1/2 cells, which is a phenomenon unique to DNA methylation inhibitors. Zebularine reactivates a silenced p16 gene and demethylated its promoter region in T24 bladder carcinoma cells[2]. Zebularine treatment inhibits cell growth in a dose and time dependent manner with an IC50 of ∼100 μM and 150 μM in MDA-MB-231 and MCF-7 cells, respectively, on 96 h exposure. At high doses zebularine induced changes in apoptotic proteins in a cell line specific manner manifested by alteration in caspase-3, Bax, Bcl2 and PARP cleavage[3]. Zebularine is also a potent competitive inhibitor of the enzyme CR deaminase. The Ki for zebularine is 0.95μM[4].
In Vivo Zebularine is only slightly cytotoxic to tumor-bearing mice. Compared with those in control mice, tumor volumes are statistically significantly reduced in mice treated with high-dose zebularine administered by intraperitoneal injection or by oral gavage[2]. Zebularine also enhances the survival time of mice with L1210 leukemia treated with 5-AZA-CdR. About 27% of the mice treated with this drug combination has a survival time longer than the mice treated with only 5-AZA-CdR[4].
Cell Assay For methylation analysis, 10T1/2 cells and T24 cells are treated with the various concentrations of zebularine. For 10T1/2 cells, the medium is changed 24 hours after the initial drug treatment, whereas for T24 cells, the medium is changed 24 hours or 48 hours after the initial drug treatment. DNA and RNA are harvested from 10T1/2 cells 72 hours after initial drug treatment and from T24 cells 96 hours after initial drug treatment. The methylation status of the indicated DNA regions is measured in two separate and independent experiments, both of which are done in duplicate[2].
Animal Admin EJ6 cells (5 × 105/injection) suspended in PBS are inoculated subcutaneously into the right and left flanks (along the midaxillary lines) of 4- to 6-week-old male BALB/c nu/nu mice. Mice (n=30) are randomLy divided into six groups (intraperitoneal control, oral control, intraperitoneal zebularine at 500 mg/kg, oral zebularine at 500 mg/kg, intraperitoneal zebularine at 1000 mg/kg, and oral zebularine at 1000 mg/kg). Each group consisted of five mice (at least six tumors per group; one or two mice per group are randomLy killed at earlier time points to establish a time course of expression). After 2–3 weeks and after macroscopic tumors (50–200 mm3) had formed, zebularine or control treatments are initiated. Zebularine, at doses of 500 mg/kg or 1000 mg/kg, is administered daily by intraperitoneal injection or oral gavage in a solution of 0.45% saline over a period of 18 days[2].
References

[1]. Champion C, et al. Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine. PLoS One. 2010 Aug 24;5(8):e12388.

[2]. Cheng JC, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst. 2003 Mar 5;95(5):399-409.

[3]. Billam M, et al. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat. 2010 Apr;120(3):581-92.

[4]. Lemaire M, et al. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol. 2009 Feb;63(3):411-6.
Density 1.7±0.1 g/cm3
Boiling Point 499.0±55.0 °C at 760 mmHg
Melting Point 160-162?C
Molecular Formula C9H12N2O5
Molecular Weight 228.202
Flash Point 255.6±31.5 °C
Exact Mass 228.074615
PSA 104.81000
LogP -1.31
Appearance solid
Vapour Pressure 0.0±2.9 mmHg at 25°C
Index of Refraction 1.697
Storage condition 2-8°C
Water Solubility DMSO: 16 mg/mL, soluble
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
RIDADR NONH for all modes of transport
WGK Germany 3
RTECS UW7539720

Chemsrc provides CAS#:3690-10-6 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 3690-10-6 | Chemsrc address: https://www.chemsrc.com/en/baike/592845.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved